NCT06223308View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 9, 2022

Primary Completion Date

May 1, 2024

Study Completion Date

October 1, 2024

Conditions
Advanced Solid TumorCervical Cancer
Interventions
DRUG

HB0028

Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Shanghai Huaota Biopharmaceutical Co., Ltd.

INDUSTRY